Medicine. Estrogen's ties to COX-2 may explain heart disease gender gap.
Couzin
Jennifer
J
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology* / Q000517:prevention & control; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004198:Disease Susceptibility; D011464:Epoprostenol / Q000096:biosynthesis; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D018384:Oxidative Stress / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D044006:Receptors, Epoprostenol / Q000235:genetics / Q000378:metabolism; D012727:Sex Characteristics
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004967:Estrogens; D007527:Isoenzymes; D008565:Membrane Proteins; D044006:Receptors, Epoprostenol; D011464:Epoprostenol; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases